Index by author

October 01, 2015; Volume 82,Issue 10

  1. Sabe, Marwa A.

    1. A new class of drugs for systolic heart failure: The PARADIGM-HF study
      A new class of drugs for systolic heart failure: The PARADIGM-HF study
      Marwa A. Sabe, MD, MPH, Miriam S. Jacob, MD and David O. Taylor, MD
      Cleveland Clinic Journal of Medicine October 2015, 82 (10) 693-701; DOI: https://doi.org/10.3949/ccjm.82a.14163

      Valsartan-sacubitril is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.

  2. Simmons, Matthew N.

    1. Genitourinary manifestations of sickle cell disease
      Surafel Gebreselassie, MD, Matthew N. Simmons, MD, PhD and Drogo K. Montague, MD
      Cleveland Clinic Journal of Medicine October 2015, 82 (10) 679-683; DOI: https://doi.org/10.3949/ccjm.82a.14029

      Sickling can lead to nephropathy, priapism, papillary necrosis, and renal medullary carcinoma.

  3. Starling, Randall C.

    1. Sacubitril-valsartan and the evolution of heart failure care
      Randall C. Starling, MD, MPH, FACC, FESC
      Cleveland Clinic Journal of Medicine October 2015, 82 (10) 702-704; DOI: https://doi.org/10.3949/ccjm.82a.15121

      It was hard to believe that any new additional therapy would make a significant difference.

Back to top

In this issue